MX2019005742A - Inhibidores de antigeno de membrana especifico de la prostata (psma) de union a albumina. - Google Patents

Inhibidores de antigeno de membrana especifico de la prostata (psma) de union a albumina.

Info

Publication number
MX2019005742A
MX2019005742A MX2019005742A MX2019005742A MX2019005742A MX 2019005742 A MX2019005742 A MX 2019005742A MX 2019005742 A MX2019005742 A MX 2019005742A MX 2019005742 A MX2019005742 A MX 2019005742A MX 2019005742 A MX2019005742 A MX 2019005742A
Authority
MX
Mexico
Prior art keywords
formula
albumin
compound
pharmaceutically acceptable
binding psma
Prior art date
Application number
MX2019005742A
Other languages
English (en)
Inventor
Berkman Clifford
Choy Cindy
Original Assignee
Cancer Targeted Tech Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Targeted Tech Llc filed Critical Cancer Targeted Tech Llc
Publication of MX2019005742A publication Critical patent/MX2019005742A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/081—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the protein being an albumin, e.g. human serum albumin [HSA], bovine serum albumin [BSA], ovalbumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D225/00—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom
    • C07D225/04—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D225/08—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with two six-membered rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Radiology & Medical Imaging (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención se relaciona con compuestos de la Fórmula (I) o una de sus sales farmacéuticamente aceptables, en donde L1 y L2 son cada uno independientemente un enlace covalente o un grupo de enlace divalente, R es un marcador detectable o un fármaco terapéutico y B es un radical de unión a albúmina. También se proporcionan composiciones que incluyen un compuesto de la Fórmula (I) junto con un vehículo farmacéuticamente aceptable, y métodos para obtener imágenes de células de cáncer de próstata usando un compuesto de Fórmula (I) .
MX2019005742A 2016-11-23 2017-11-24 Inhibidores de antigeno de membrana especifico de la prostata (psma) de union a albumina. MX2019005742A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662425810P 2016-11-23 2016-11-23
PCT/US2017/063182 WO2018098390A1 (en) 2016-11-23 2017-11-24 Albumin-binding psma inhibitors

Publications (1)

Publication Number Publication Date
MX2019005742A true MX2019005742A (es) 2019-09-13

Family

ID=60812130

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019005742A MX2019005742A (es) 2016-11-23 2017-11-24 Inhibidores de antigeno de membrana especifico de la prostata (psma) de union a albumina.

Country Status (8)

Country Link
US (1) US11147889B2 (es)
EP (1) EP3544960A1 (es)
JP (1) JP7167021B2 (es)
CN (1) CN109982998A (es)
BR (1) BR112019010206A2 (es)
CA (1) CA3043619A1 (es)
MX (1) MX2019005742A (es)
WO (1) WO2018098390A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3700917A4 (en) * 2017-10-22 2021-08-04 Provincial Health Services Authority NEW RADIOMETAL BINDING COMPOUNDS FOR THE DIAGNOSIS OR TREATMENT OF CANCER EXPRESSING A PROSTATE-SPECIFIC MEMBRANARY ANTIGEN
US20210276971A1 (en) * 2018-06-20 2021-09-09 The Research Foundation For The State University Of New York Triazamacrocycle-derived chelator compositions for coordination of imaging and therapy metal ions and methods of using same
EP3880253A1 (en) * 2018-11-14 2021-09-22 Noria Therapeutics, Inc. Thioamide-containing compositions and methods of use thereof
WO2020108753A1 (en) * 2018-11-28 2020-06-04 ITM Isotopen Technologien München AG Novel tumor antigen binding agents and uses thereof
CA3144094A1 (en) 2019-06-21 2020-12-24 Provincial Health Services Authority Radiolabeled compounds targeting the prostate-specific membrane antigen
CA3174082A1 (en) 2020-03-04 2021-09-10 Nihon Medi-Physics Co., Ltd. Compound and radioactive labeling compound
WO2022120226A1 (en) * 2020-12-04 2022-06-09 The Regents Of The University Of California Peptide receptor radionuclide therapy
CA3201655A1 (en) * 2020-12-16 2022-06-23 Francois Benard Radiolabeled compounds targeting the prostate-specific membrane antigen
CN114685599A (zh) * 2020-12-30 2022-07-01 南京江原安迪科正电子研究发展有限公司 一种psma靶向抑制剂及放射性核素标记的psma靶向抑制剂、制备方法和用途
CA3210294A1 (en) * 2021-03-04 2022-09-09 Yoshifumi Maya Compound and radioactive labeling compound
WO2023164775A1 (en) * 2022-03-04 2023-09-07 Provincial Health Services Authority Radiolabeled compounds targetng the prostate-specific membrane antigen
WO2024126687A1 (en) * 2022-12-16 2024-06-20 Silence Therapeutics Gmbh Nucleic acids conjugated to an albumin binding moiety

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0621973D0 (en) * 2006-11-03 2006-12-13 Philogen Spa Binding molecules and uses thereof
US9056841B2 (en) * 2009-03-19 2015-06-16 The Johns Hopkins University PSMA-targeting compounds and uses thereof
WO2013022797A1 (en) * 2011-08-05 2013-02-14 Molecular Insight Pharmaceuticals Radiolabeled prostate specific membrane antigen inhibitors
US10011632B2 (en) * 2011-08-22 2018-07-03 Siemens Medical Solutions Usa, Inc. PSMA imaging agents
US20160257961A1 (en) * 2013-11-06 2016-09-08 Solstice Biologics, Ltd. Polynucleotide constructs having disulfide groups
AU2014348601A1 (en) * 2013-11-14 2016-05-26 Endocyte, Inc. Compounds for positron emission tomography
EP3183236B1 (en) * 2014-08-24 2022-04-20 Max-Planck-Gesellschaft zur Förderung der Wissenschaften Method for the production of 18f-labeled active esters and their application exemplified by the preparation of a psma-specific pet-tracer
HUE053064T2 (hu) * 2015-09-30 2021-06-28 Deutsches Krebsforsch Prosztataspecifikus membránantigén (PSMA) 18F-címkézett inhibitorai és azok alkalmazása képalkotó ágensként prosztatarákkal
WO2017165473A1 (en) * 2016-03-22 2017-09-28 The Johns Hopkins University Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer
EP3474903A4 (en) * 2016-06-23 2020-02-26 Cornell University DUAL TARGETING CONSTRUCTIONS FOR INFLUENCING TUMOR ELIMINATION
DE102016122273B4 (de) * 2016-11-18 2018-06-21 Abx Advanced Biochemical Compounds Gmbh Präkursoren für die Radiofluorierung

Also Published As

Publication number Publication date
BR112019010206A2 (pt) 2019-09-03
US11147889B2 (en) 2021-10-19
EP3544960A1 (en) 2019-10-02
JP2019535754A (ja) 2019-12-12
JP7167021B2 (ja) 2022-11-08
CA3043619A1 (en) 2018-05-31
CN109982998A (zh) 2019-07-05
WO2018098390A1 (en) 2018-05-31
US20200061218A1 (en) 2020-02-27

Similar Documents

Publication Publication Date Title
MX2019005742A (es) Inhibidores de antigeno de membrana especifico de la prostata (psma) de union a albumina.
CY1120480T1 (el) Ενωσεις πυραζολοπυριμιδινης
PH12018500591A1 (en) Heterocyclic compounds and uses thereof
CY1125021T1 (el) Κιναζολινες ως αναστολεις διαυλων ιοντων καλιου
PH12018502227A1 (en) Macrocyclic mcl1 inhibitors for treating cancer
TN2019000263A1 (en) Macrocyclic compounds as ros1 kinase inhibitors
CL2013000935A1 (es) Compuestos derivados de bencimidazol o sus sales, como inhibidores de cinasa pi3; composicion farmaceutica que los comprende; y su uso para el tratamiento de un neoplasma deficiente en pten seleccionado entre gliomas de cerebro, cancer de mama, cancer de prostata, cancer gastrico y mieloma multiple, entre otros.
PH12019501029A1 (en) Fgfr4 inhibitor, preparation method therefor and pharmaceutical use therefor
MX2019001053A (es) Inhibidores de antigeno de la membrana especifico para la prostata (psma) quelados.
MX352672B (es) Compuestos heterocíclicos como inhibidores de mdm2 para el tratamiento del cáncer.
PH12015500360A1 (en) Pyrazolopyrimidine compound
WO2011116299A3 (en) Myeloid derived suppressor cell inhibiting agents
GEP20237479B (en) Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
MX2023004309A (es) Inhibidores de quinasa alk2 que contienen imidazol.
EA201692542A1 (ru) Индановые и индолиновые производные и их применение в качестве активаторов растворимой гуанилатциклазы
EP3483143A8 (en) Piperidinone derivatives as mdm2 inhibitors for the treatment of cancer
MX2013005445A (es) Pirazolopiridinas y el uso de pirazolopiridinas como inhibidores de tirosina cinasa 2 (tyk2).
EA201290237A1 (ru) Киназные ингибиторы
EA201170872A1 (ru) Ингибиторы протеинкиназы
EA201491362A1 (ru) Анестезирующие соединения и способы их применения
MY197127A (en) Pyrrolobenzodiazepine conjugates
MX2021006544A (es) Inhibidores de cinasa dependiente de ciclina 9 (cdk9) y polimorfos de los mismos para uso como agentes para el tratamiento de cancer.
TW201613938A (en) Selective inhibitors for protein kinases, a pharmaceutical composition and an use thereof
EA202193015A1 (ru) Ингибиторы cdk
AR047531A1 (es) Derivados 1h-tieno(2,3-c)pirazol utiles como inhibidores de quinasa